Survey Reveals ‘Striking’ Barriers to Accessing High-Priority Cancer Drugs
Respondents said some essential cancer drugs had substantial out-of-pocket costs, and some posed a high risk of catastrophic expenditure.
Breast Cancer
Pandemic-Related Delays in Cancer Surgery May Not Affect Short-Term Outcomes
There was no increase in unresectable disease, new metastatic disease, or 30-day mortality associated with increasing delays.
Breast, Prostate Cancer Common in Patients With COVID-19 and Cancer History
For patients hospitalized with COVID-19, prostate cancer was the most common cancer type across all databases.
Financial Burden Increasing for Privately Insured Cancer Patients
There was a significant increase in out-of-pocket costs for all 4 cancer types studied.
Model More Accurately Predicts Outcomes of Radiotherapy in Cancer Patients
The genomic-adjusted radiation dose (GARD) model predicts outcomes of radiotherapy.
Tecentriq Indication for Triple-Negative Breast Cancer Withdrawn
In 2019, the FDA granted accelerated approval to Tecentriq, a PD-L1 blocking antibody, for unresectable locally advanced or metastatic TNBC.
Overcoming Obstacles to Health Equity in Breast Cancer Prevention and Control
The current scientific evidence may not be generalizable to underrepresented groups.
On-Treatment Ki-67: A Promising Prognostic Marker for Early Breast Cancer Management
Dr Alan Lyss reviews results from the high-risk cohort of the WSG-ADAPT HR+/HER2- trial.
Changes in Clinical Trial Conduct Prompted by the COVID-19 Pandemic Should Persist
The AACR COVID-19 and Cancer Task Force recommends keeping changes to clinical trial practices that were prompted by the pandemic.
Incidence of Axillary Adenopathy After COVID-19 Vaccination May Be Lower Than Previously Thought
Prior data suggested the incidence may be as high as 16%.
- Loading...
Loading...
Loading... 
Loading...